https://pmc.ncbi.nlm.nih.gov/articles/PMC5782154/
1331: The SOLO Studies: A Single-Dose of Oritavancin (ORI) Compared to 7-10 Days of Vancomycin...
https://pmc.ncbi.nlm.nih.gov/articles/PMC4319806/
Oritavancin Diphosphate - PMC
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3...
oritavancin diphosphatepmc
https://www.science20.com/news_articles/oritavancin_one_and_done_antibiotic_could_reduce_mrsa-137873
Oritavancin: One And Done Antibiotic Could Reduce MRSA | Science 2.0
Methicillin-resistant Staphylococcus aureus (MRSA) has become the poster child for antibiotic resistance in large part because of a larger problem: patients...
one and donescience 2oritavancinantibiotic
https://pmc.ncbi.nlm.nih.gov/articles/PMC4811835/
Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections - PMC
Resistance among Gram-positive organisms has been steadily increasing over the last several years; however, the development of new antibiotics to treat...
https://pmc.ncbi.nlm.nih.gov/articles/PMC4334198/
Oritavancin for the treatment of acute bacterial skin and skin structure infections: an...
The emergence of resistance to glycopeptide antibiotics such as vancomycin and teicoplanin among Gram-positive bacteria has spurred the search for...
for the
https://pmc.ncbi.nlm.nih.gov/articles/PMC2764228/
Oritavancin Population Pharmacokinetics in Healthy Subjects and Patients with Complicated Skin and...
Oritavancin is a novel glycopeptide antimicrobial agent with potent in vitro activity against a wide variety of gram-positive bacteria, including...
population pharmacokineticsoritavancinhealthy